Metastatic Prostate Cancer Prognosis
Comprehensive prognostic assessment for mCRPC and mHSPC using validated clinical factors and Halabi model framework
Did our AI summary help? Let us know.
Low risk: median survival >32 months Very high risk: median survival ~9 months Visceral metastases carry strongest weight
Ready to run the numbers?
Why: Prognostic stratification guides treatment intensity and helps patients understand expected outcomes.
How: Multi-factor scoring based on ECOG, PSA, ALP, LDH, hemoglobin, albumin, metastatic burden, and treatment history.
Run the calculator when you are ready.
🏥 Sample Clinical Scenarios — Click to Load
Patient Demographics
Laboratory Values
Disease Burden
For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
ECOG and visceral mets are strongest prognostic factors
— NCCN
Halabi model uses 12 validated variables
— Clinical trials
📋 Key Takeaways
- • Prognosis varies widely: low-risk median survival >32 months vs very high-risk ~9 months
- • ECOG performance status and visceral metastases are the strongest prognostic factors
- • mHSPC responds to hormone therapy; mCRPC progresses despite castrate testosterone
- • Treatment intensification (triplet therapy) benefits high-volume mHSPC
- • Halabi model incorporates 12 validated prognostic variables
💡 Did You Know?
📖 How It Works
The calculator uses a multi-factor scoring system based on the Halabi model and CHAARTED/LATITUDE trial data.
Step 1: Data Collection
12 key clinical parameters: performance status, PSA, ALP, LDH, hemoglobin, albumin, metastatic burden, treatment history.
Step 2: Factor Weighting
Each factor is weighted by prognostic significance. Visceral metastases and poor ECOG carry the highest weights.
Step 3: Risk Stratification
Low (0-4 pts), Intermediate (4.1-8), High (8.1-12), Very High (>12). Each group has associated survival estimates.
🎯 Expert Tips
Low Risk: Maximize Outcomes
Consider aggressive multimodal therapy, novel hormonal agents, and clinical trial enrollment.
Intermediate: Balance Efficacy & QoL
Treatment intensification with combination therapy; more frequent monitoring.
High Risk: Early Palliative Care
Integrate palliative care early; consider triplet therapy if eligible.
Very High: Goals of Care
Focus on quality of life; goals of care discussions with patient and family.
⚖️ This Tool vs Alternatives
| Feature | This Calculator | Manual Calculation |
|---|---|---|
| Halabi-derived risk score | ✅ | ❌ |
| Survival estimates | ✅ | ❌ |
| Risk/protective factor list | ✅ | ❌ |
| Treatment recommendations | ✅ | ❌ |
| Visual charts | ✅ | ❌ |
❓ FAQ
mHSPC vs mCRPC?
mHSPC responds to ADT; mCRPC progresses despite castrate testosterone (<50 ng/dL). Transition typically occurs after 18-36 months of hormone therapy.
How accurate are survival estimates?
Population-based from trials; individual outcomes vary with treatment response and new therapies.
Why are visceral mets important?
Indicate aggressive biology; key stratification factor for treatment intensity.
When to reassess prognosis?
At treatment start, progression, new symptoms, and every 3-6 months during stable disease.
What is ECOG Performance Status?
Scale 0-4: 0=fully active, 1=restricted, 2=ambulatory no work, 3=limited self-care, 4=completely disabled.
What treatments for high-risk patients?
Triplet therapy (ADT + docetaxel + novel hormonal agent), PARP inhibitors for BRCA mutations, Lu-177 PSMA for PSMA-positive disease.
📊 Key Statistics
📚 Official Sources
⚠️ Disclaimer: This calculator is for educational purposes only. Prognostic estimates are population-based. All treatment decisions should involve your oncology team.
Related Calculators
EORTC Bladder Cancer Recurrence and Progression Calculator
Calculate EORTC risk scores for non-muscle invasive bladder cancer (NMIBC) to predict recurrence and progression probabilities based on tumor characteristics.
HealthKidney STONE Calculator for Percutaneous Nephrolithotomy
Calculate the STONE nephrolithometry score to predict stone-free rates and complications for PCNL procedures based on stone size, tract length, obstruction...
HealthTTKG Calculator - Transtubular Potassium Gradient
Calculate the transtubular potassium gradient to assess renal potassium handling and differentiate causes of hyperkalemia and hypokalemia.
HealthUrine Output Calculator
Calculate and interpret urine output for assessment of kidney function, fluid balance, and acute kidney injury (AKI) staging using KDIGO criteria.
HealthAbsolute Neutrophil Count (ANC) Calculator
Calculate Absolute Neutrophil Count including band neutrophils. Assess neutropenia severity, infection risk, febrile neutropenia status, and guide clinical...
HealthCharlson Comorbidity Index Calculator
Calculate the Charlson Comorbidity Index (CCI) to predict 10-year mortality. Weights 17 comorbid conditions and includes age adjustment for comprehensive...
Health